ER, PR, HER2/NEU STATUS AND RELATION TO CLINICOPATHOLOGICAL FACTORS IN BREAST CARCINOMA

  • Ritu Yadav Department of Genetics, M.D. University, Rohtak-124001
  • Rajeev Sen
  • Preeti Chauhan

Abstract

Objective: The role of hormone receptors as a prognostic and therapeutic tool in breast cancer is widely accepted. The aim of this study was to the analysis of steroid receptor status in breast cancer with clinic pathological characteristics.

Methods: In the present study, immunohistochemical assay of two hundred tumor block of patients of breast carcinoma was performed to know the hormone receptor status as well as histological examination.

Results: 150 samples were grouped to study hormonal status and their relation with clinic-pathological factors. The results in the present study documented the 42.3 %, 37.6 % and 56.2 % expression rate of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (Her2/neu) (. The negative expression of ER, PR receptors found higher (57.7 %, 62.4 % respectively). However, Her2/neu positive expression found higher than negative expression (43.8 %). An inverse correlation of Her2/neu expression with ER and PR expression was observed (p=0.007). A significant association of tumor size was observed with ER and PR expression (p=0.02 & p=0.04 respectively). However, no statistically significant association was observed between Her2/neu expression and tumor size (p=0.84).<4 positive lymph nodes showed more no reactivity of the receptors (ER, PR & Her2/neu) than>4 positive lymph nodes. No significant association of lymph node status and histological types was found with receptor expression.

Conclusion: In conclusion further functional analyzes of ER, PR and Her2 receptors are needed to investigate the effects of compounds in inhibiting cancer in humans.

Keywords: Breast carcinoma, Estrogen, Her-2/neu receptor, Immunohistochemistry, Progesterone

 

Keywords: Breast carcinoma, Estrogen, Her-2/neu receptor, Immunohistochemistry, Progesterone

Downloads

Download data is not yet available.

References

1. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002;38:99-166.
2. Colditz GA, Bernard A, Rosner WY, Chen MD, Holmes SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004;96:218-28.
3. Ward TH, Cummings J, Dean E, Greystoke A, Hou JM, Backen A. Biomarkers of apoptosis. Br J Cancer 2000;99:841-6.
4. Looi LM, Cheah PL. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast correlates to high histologic grade and loss of estrogen receptor protein. Malays J Pathol 1998;20:19-23.
5. Pinto AE, Andre S, Pareira T, Nobrega S, Soares J. C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol 2001;12:525-33.
6. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007;9:6.
7. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
8. Bardou JV, Arpino G, Elledge RM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973–9.
9. Bloom H, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359.
10. Donegan WL. Tumor-related prognostic factors for breast cancer. Cancer J Clin 1997;47:28-51.
11. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM. 2000 update of recommendations for use of tumor markers in breast and colorectal cancer: clinical practice guidelines of American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
12. Lakmini KB. Quick score of hormone receptor status of breast carcinoma: Correlation with the other clinicopathological prognostic parameters. Indian J Pathol Bacteriol 2009;52:159-63.
13. Kaul R, Sharma J, Minhas SS, Mardi K. Hormone receptor status of breast cancer in the himalayan region of northern India. Indian J Surg 2011;73:9-12.
14. Biesterfield S, Schroder W. Simultaneous histochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information. Aus Cancer Res 1979;7:4723-9.
15. Rosai J. Rosai and Ackerman's surgical pathology. 8th ed. Mosby, Edinburg; 1996. p. 1786-820.
16. Kapicl IT, Ušaj KS, Panjković M, Ivanović DD, Golubović M. HER-2/neu overexpression in invasive ductal breast cancer–an association with other prognostic and predictive factors. Arch Oncol 2007;15:15-8.
17. Ayadi L, Khabir A, Amouri H, Karray S, Dammak A, Guermazi M, et al. Correlation of HER-2 over-expression with clinicopathological parameters in Tunisian breast carcinoma. World J Surgical Oncol 2008;6:112.
18. Janet L, Raymond S. Breast cancer incidence in young women by estrogen receptor status and race. Am J Public Health 1989;79:71-3.
19. Slamon DJ, Clark GM. Amplification of C-ERB-B2 and aggressive breast tumors? Science 1988;240:1795-8.
20. Naeem M, Nasir A, Aman Z, Ahmad T, Samad A. Frequency of her-2/neu receptor positivity and its association with other features of breast cancer. J Ayub Med College Abbottabad 2008;20:23-6.
21. Desai SB, Moonim MT, Gill AK. Hormone receptor status of breast cancer in India. A study of 798 tumors. Breast 2000;9:267-70.
22. Raina V, Taneja V, Gulati A, Deo SVS, Shukla NK, Vij U. Oestrogen receptor status in breast cancer. Indian Pract 2000;53:405-7.
23. Moghadaszadeh M, Nikanfar A, Hemati M, Gharib B, Sardasti S. Interaction between Her2 and hormone receptors in breast cancer. Int J Hematol Oncol Stem Cell Res 2010;9:14-6.
24. Suvarchala SB, Nageswararao R. Carcinoma breast-histopathological and hormone receptors correlation. J Biosci Technol 2011;2:340-8.
25. Azam M, Qureshi A, Mansoor S. Comparison of estrogen receptors, progesterone receptors and HER-2/neu expression between primary and metastatic breast carcinoma. J Pak Med Assoc 2009;59:736-40.
26. Prati R, Apple SK, He J, Gornbei JA, Chanh HR. Histopathologic characteristics are predicting HER-2/neu amplification in breast cancer. Breast J 2005;11:433-9.
27. Ariga R, Zarif A, Korasick J, Reddy V, Siziopicou K, Gattuso P. Correlation of Her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 2005;1:278-80.
28. Bozcuk H, Uslu G, Pestereli E, Samur M, Ozdogan M, Karaveli S. Predictor of distant metastasis at a presentation in breast cancer: a study also evaluating associations among common biological indicators. Breast Cancer Res Treat 2001;68:239-48.
29. Tokatli F, Altaner S, Uzal C, Ture M, Kocak Z, Uygun K. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients. Exp Oncol 2005;27:145-9.
30. Richard J. Interaction between estrogen and growth factor receptors in human breast cancer. Breast J 2003;9:361-73.
31. Fatima S, Faridi N, Gill S. Breast Cancer, Steroid receptors, and other prognostic indicators. J College Physicians Surgeons Pakistan 2005;15:230-3.
Statistics
348 Views | 1387 Downloads
How to Cite
Yadav, R., R. Sen, and P. Chauhan. “ER, PR, HER2/NEU STATUS AND RELATION TO CLINICOPATHOLOGICAL FACTORS IN BREAST CARCINOMA”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 8, no. 4, Apr. 2016, pp. 287-90, https://innovareacademics.in/journals/index.php/ijpps/article/view/10776.
Section
Original Article(s)